Delving into the Latest Updates on Carteolol Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Carteolol, Carteolol hydrochloride (JP17/USP)

+ [13]

Target

β1-adrenergic receptor x β2-adrenergic receptor x β3-adrenergic receptor

Action

antagonists

Mechanism

β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists), β2-adrenergic receptor antagonists(Beta-2 adrenergic receptor antagonists), β3-adrenergic receptor antagonists(Beta-3 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEye Diseases

Active Indication

GlaucomaCataractOcular Hypertension+ [3]

Inactive Indication-

Originator Organization

Otsuka Pharmaceutical Co., Ltd.

Active Organization

Otsuka Pharmaceutical Co., Ltd.

China Otsuka Pharmaceutical Co., Ltd.

Inactive Organization

Novartis Pharmaceuticals Corp.

AbbVie, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (25 Oct 1980),

Angina PectorisArrhythmias, CardiacHypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC16H24N2O3

InChIKeyLWAFSWPYPHEXKX-UHFFFAOYSA-N

CAS Registry51781-06-7

View All Structures (2)

Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution. - Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution.

Start Date11 Jan 2017

Sponsor / Collaborator-

100 Clinical Results associated with Carteolol Hydrochloride

Login to view more data

100 Translational Medicine associated with Carteolol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Carteolol Hydrochloride

Login to view more data

1,023

Literatures (Medical) associated with Carteolol Hydrochloride

01 Apr 2025·International Journal of Biological Macromolecules

High-viscosity dietary fibers modulate gut microbiota and liver metabolism to prevent obesity in high-fat diet-fed mice

Article

Author: Higashimura, Yasuki ; Nagano, Takao ; Lelo, Aaron Pambu ; Nakano, Masataka ; Nishiuchi, Takumi

Obesity and metabolic disorders are rising global health concerns, emphasizing the need for effective dietary interventions. High-viscosity dietary fibers such as bacterial cellulose (BC) and guar gum (GG) have unique properties that may complement each other in modulating gut microbiota and metabolic health. This study investigates their effects in high-fat diet-fed mice. BC and GG increase Bacteroides, which degrade polysaccharides and produce short-chain fatty acids (SCFAs), supporting metabolic health. BC enhances bile acid excretion and enriches Faecalibaculum, Duncaniella, and Paramuribaculum, promoting gut barrier integrity and reducing inflammation, potentially improving bile acid turnover and lipid metabolism. GG more effectively increases butyrate production by enhancing butyrate-producing bacteria, such as Clostridium XIVa and Kineothrix, and promotes Bifidobacterium, strengthening anti-inflammatory effects and gut barrier function. Both fibers upregulate bile acid biosynthesis, but BC's non-fermentable nature leads to higher bile acid excretion, while GG's fermentation causes lower excretion and broader liver metabolic changes. Both fibers reduce body weight, fat accumulation, and cholesterol levels, highlighting their potential in managing obesity and metabolic disorders. The complementary effects of BC and GG underscore the importance of fiber diversity for targeted dietary strategies to improve metabolic health.

01 Mar 2025·Fundamental & Clinical Pharmacology

Adrenaline enhances nociceptive and motor blockades by intrathecal carteolol and oxprenolol in rats

Article

Author: Chen, Yu‐Wen ; Liu, Chieh‐Yu ; Hung, Ching‐Hsia ; Chiu, Chong‐Chi ; Liu, Kuo‐Sheng ; Wang, Jhi‐Joung

AbstractBackgroundThis study examined the effects of beta‐blockers and the combination of carteolol/oxprenolol with epinephrine on spinal nociceptive and motor blockades and compared them with propranolol.MethodsNociceptive and motor blockades were assessed in rats after intrathecal injection of carteolol, oxprenolol, metoprolol, acebutolol, and sotalol. Carteolol and oxprenolol were used in combination with epinephrine for spinal nociceptive and motor blockades. Propranolol was used as a control.ResultsAt the same dose of 0.6 μmol, carteolol and oxprenolol are more potent than propranolol, and the duration of action of carteolol and oxprenolol is longer than or the same as that of propranolol. At ED50 (50% effective dose), the potency rankings of drugs are carteolol > oxprenolol > propranolol (P > 0.01). At ED25, ED50, and ED75, the time to full recovery induced by carteolol was longer than that induced by oxprenolol or propranolol. When 1:40,000 epinephrine was added to beta‐blocker (carteolol, oxprenolol, and propranolol) at ED50, spinal blockades and duration of action were increased compared to beta‐blockers alone (P > 0.05).ConclusionCarteolol and oxprenolol are more effective than propranolol on spinal blockades, while other beta‐blockers are relatively ineffective. Compared to propranolol, the duration of action of carteolol and oxprenolol is longer or the same. Epinephrine enhances spinal blockades of carteolol, oxprenolol, and propranolol, suggesting that alpha‐adrenergic receptors may play an important role in enhancing the anti‐nociceptive effects of beta‐blockers.

01 Feb 2025·Natural Product Research

Natural 3,4-dihydro-2(1 H )-quinolinones- Part I: plant sources

Review

Author: Khadem, Shahriar ; Marles, Robin J.

While natural products have undoubtedly played a pivotal role in drug discovery, their potential as lead compounds has been hindered by challenges such as limited accessibility and complex synthesis processes. At the core of numerous natural and synthetic compounds, each exhibiting remarkable biological traits, lies the foundational structure of 3,4-dihydro-2(1H)-quinolinone, also known as 2-oxo-tetrahydroquinoline (2 O-THQ). This article extensively examines the occurrence of 2 O-THQ alkaloids across the plant kingdom, exploring their capacity to serve as a source for innovative bioactive natural products. Despite the undeniable significance of these compounds, the existing body of review literature has yet to provide comprehensive coverage, underscoring the pivotal contribution of this present article in investigating their prevalence in nature.

100 Deals associated with Carteolol Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00599	Carteolol Hydrochloride	S01ED05 C07AA15	DB00521

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	China	China Otsuka Pharmaceutical Co., Ltd.	01 Jan 1995
Cataract	Japan	Otsuka Pharmaceutical Co., Ltd.	15 Feb 1984
Ocular Hypertension	Japan	Otsuka Pharmaceutical Co., Ltd.	15 Feb 1984
Angina Pectoris	Japan	Otsuka Pharmaceutical Co., Ltd.	25 Oct 1980
Arrhythmias, Cardiac	Japan	Otsuka Pharmaceutical Co., Ltd.	25 Oct 1980
Hypertension	Japan	Otsuka Pharmaceutical Co., Ltd.	25 Oct 1980